Thermal Stability as a Determinant of AAV Serotype Identity

Molecular Therapy Methods and Clinical Development

Volumn 6, Issue , 2017, Pages 171-182

  Bennett, Antonette ^a   Patel, Saajan ^a   Mietzsch, Mario ^a   Jose, Ariana ^a   Lins Austin, Bridget ^a,c   Yu, Jennifer C ^a   Bothner, Brian ^b   McKenna, Robert ^a   Agbandje McKenna, Mavis ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

AAV; AAV buffer formulations; AAV capsid stability; AAV serotype identification; AAV vector buffers; adeno associated virus; differential scanning fluorimetry; parvovirus stability; viral vectors

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; AMINO ACID; PROTEIN VP1; PROTEIN VP2;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 1; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 3; ADENO ASSOCIATED VIRUS 4; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 6; ADENO ASSOCIATED VIRUS 7; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL SCANNING FLUORIMETRY; FLUOROMETRY; GOOD MANUFACTURING PRACTICE; MELTING TEMPERATURE; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT ADENO ASSOCIATED VIRUS 10; SEROTYPE; THERMOSTABILITY; VIRUS CAPSID; VIRUS GENOME; VIRUS RECOMBINANT;

EID: 85029303745     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1016/j.omtm.2017.07.003     Document Type: Article

References (51)

1. Gao, G., Vandenberghe, L.H., Alvira, M.R., Lu, Y., Calcedo, R., Zhou, X., Wilson, J.M., Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78 (2004), 6381–6388.
2. Rose, J.A., Maizel, J.V. Jr., Inman, J.K., Shatkin, A.J., Structural proteins of adenovirus-associated viruses. J. Virol. 8 (1971), 766–770.
3. Snijder, J., van de Waterbeemd, M., Damoc, E., Denisov, E., Grinfeld, D., Bennett, A., Agbandje-McKenna, M., Makarov, A., Heck, A.J., Defining the stoichiometry and cargo load of viral and bacterial nanoparticles by Orbitrap mass spectrometry. J. Am. Chem. Soc. 136 (2014), 7295–7299.
4. Girod, A., Wobus, C.E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J.A., Hallek, M., The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen. Virol. 83 (2002), 973–978.
5. Zádori, Z., Szelei, J., Lacoste, M.C., Li, Y., Gariépy, S., Raymond, P., Allaire, M., Nabi, I.R., Tijssen, P., A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 1 (2001), 291–302.
6. Hastie, E., Samulski, R.J., Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success–a personal perspective. Hum. Gene Ther. 26 (2015), 257–265.
7. Gray, J.T., Zolotukhin, S., Design and construction of functional AAV vectors. Methods Mol. Biol. 807 (2011), 25–46.
8. Flotte, T.R., Adeno-associated virus-based gene therapy for inherited disorders. Pediatr. Res. 58 (2005), 1143–1147.
9. Srivastava, A., In vivo tissue-tropism of adeno-associated viral vectors. Curr. Opin. Virol. 21 (2016), 75–80.
10. Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R.J., Walsh, C.E., Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2 (2000), 619–623.
11. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, A.J., Harrington, C., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365 (2011), 2357–2365.
12. Gaudet, D., Méthot, J., Kastelein, J., Gene therapy for lipoprotein lipase deficiency. Curr. Opin. Lipidol. 23 (2012), 310–320.
13. Tardieu, M., Zérah, M., Husson, B., de Bournonville, S., Deiva, K., Adamsbaum, C., Vincent, F., Hocquemiller, M., Broissand, C., Furlan, V., et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum. Gene Ther. 25 (2014), 506–516.
14. Tseng, Y.S., Vliet, K.V., Rao, L., McKenna, R., Byrne, B.J., Asokan, A., Agbandje-McKenna, M., Generation and characterization of anti-adeno-associated virus serotype 8 (AAV8) and anti-AAV9 monoclonal antibodies. J. Virol. Methods 236 (2016), 105–110.
15. Tseng, Y.S., Agbandje-McKenna, M., Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front. Immunol., 5, 2014, 9.
16. Wobus, C.E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., Kleinschmidt, J.A., Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74 (2000), 9281–9293.
17. Kuck, D., Kern, A., Kleinschmidt, J.A., Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J. Virol. Methods 140 (2007), 17–24.
18. Van Vliet, K., Mohiuddin, Y., McClung, S., Blouin, V., Rolling, F., Moullier, P., Agbandje-McKenna, M., Snyder, R.O., Adeno-associated virus capsid serotype identification: analytical methods development and application. J. Virol. Methods 159 (2009), 167–177.
19. Mietzsch, M., Grasse, S., Zurawski, C., Weger, S., Bennett, A., Agbandje-McKenna, M., Muzyczka, N., Zolotukhin, S., Heilbronn, R., OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy. Hum. Gene Ther. 25 (2014), 212–222.
20. Miller, E.B., Gurda-Whitaker, B., Govindasamy, L., McKenna, R., Zolotukhin, S., Muzyczka, N., Agbandje-McKenna, M., Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 62 (2006), 1271–1274.
21. Huang, X., Hartley, A.V., Yin, Y., Herskowitz, J.H., Lah, J.J., Ressler, K.J., AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications. J. Virol. Methods 193 (2013), 270–277.
22. Rayaprolu, V., Kruse, S., Kant, R., Movahed, N., Brooke, D., Bothner, B., Fluorometric estimation of viral thermal stability. Biol. Protoc., 4, 2014, e1199.
23. Brooke, D., Mohaved, N., Bothner, B., Universal buffers for use in biochemistry and biophysical experiments. AIMS Biophysics 2 (2015), 336–342.
24. Urabe, M., Ding, C., Kotin, R.M., Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13 (2002), 1935–1943.
25. Warrington, K.H. Jr., Gorbatyuk, O.S., Harrison, J.K., Opie, S.R., Zolotukhin, S., Muzyczka, N., Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J. Virol. 78 (2004), 6595–6609.
26. Rabinowitz, J.E., Xiao, W., Samulski, R.J., Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265 (1999), 274–285.
27. Sonntag, F., Schmidt, K., Kleinschmidt, J.A., A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107 (2010), 10220–10225.
28. Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam, H., Remmert, M., Söding, J., et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol., 7, 2011, 539.
29. Gasteiger, E., Gattiker, A., Hoogland, C., Ivanyi, I., Appel, R.D., Bairoch, A., ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31 (2003), 3784–3788.
30. Wu, Z., Asokan, A., Grieger, J.C., Govindasamy, L., Agbandje-McKenna, M., Samulski, R.J., Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80 (2006), 11393–11397.
31. Wright, J.F., Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther. 15 (2008), 840–848.
32. Aitken, M.L., Moss, R.B., Waltz, D.A., Dovey, M.E., Tonelli, M.R., McNamara, S.C., Gibson, R.L., Ramsey, B.W., Carter, B.J., Reynolds, T.C., A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum. Gene Ther. 12 (2001), 1907–1916.
33. Flotte, T.R., Mueller, C., Gene therapy for alpha-1 antitrypsin deficiency. Hum. Mol. Genet. 20 (2011), R87–R92.
34. Bainbridge, J.W., Smith, A.J., Barker, S.S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G.E., Stockman, A., Tyler, N., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358 (2008), 2231–2239.
35. Rayaprolu, V., Kruse, S., Kant, R., Venkatakrishnan, B., Movahed, N., Brooke, D., Lins, B., Bennett, A., Potter, T., McKenna, R., et al. Comparative analysis of adeno-associated virus capsid stability and dynamics. J. Virol. 87 (2013), 13150–13160.
36. Osting, S., Bennett, A., Power, S., Wackett, J., Hurley, S.A., Alexander, A.L., Agbandje-Mckena, M., Burger, C., Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum. Mol. Ther. Methods Clin. Dev., 1, 2014, 4.
37. Boye, S.L., Bennett, A., Scalabrino, M.L., McCullough, K.T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., Boye, S.E., Impact of heparan sulfate binding on transduction of retina by recombinant adeno-associated virus vectors. J. Virol. 90 (2016), 4215–4231.
38. Pacouret, S., Bouzelha, M., Shelke, R., Andres-Mateos, E., Xiao, R., Maurer, A., Mevel, M., Turunen, H., Barungi, T., Penaud-Budloo, M., et al. AAV-ID: a rapid and robust assay for batch-to-batch consistency evaluation of AAV preparations. Mol. Ther. 25 (2017), 1375–1386.
39. Zeng, C., Moller-Tank, S., Asokan, A., Dragnea, B., Probing the link among genomic cargo, contact mechanics, and nanoindentation in recombinant adeno-associated virus 2. J. Phys. Chem. B 121 (2017), 1843–1853.
40. Mietzsch, M., Casteleyn, V., Weger, S., Zolotukhin, S., Heilbronn, R., OneBac 2.0: Sf9 cell lines for production of AAV5 vectors with enhanced infectivity and minimal encapsidation of foreign DNA. Hum. Gene Ther. 26 (2015), 688–697.
41. Kohlbrenner, E., Aslanidi, G., Nash, K., Shklyaev, S., Campbell-Thompson, M., Byrne, B.J., Snyder, R.O., Muzyczka, N., Warrington, K.H. Jr., Zolotukhin, S., Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol. Ther. 12 (2005), 1217–1225.
42. Govindasamy, L., Padron, E., McKenna, R., Muzyczka, N., Kaludov, N., Chiorini, J.A., Agbandje-McKenna, M., Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 80 (2006), 11556–11570.
43. Ling, C., Lu, Y., Cheng, B., McGoogan, K.E., Gee, S.W., Ma, W., Li, B., Aslanidi, G.V., Srivastava, A., High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors. J. Vis. Exp., 2011, 2538.
44. Elmallah, M.K., Falk, D.J., Nayak, S., Federico, R.A., Sandhu, M.S., Poirier, A., Byrne, B.J., Fuller, D.D., Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. Mol. Ther. 22 (2014), 702–712.
45. Graham, T., McIntosh, J., Work, L.M., Nathwani, A., Baker, A.H., Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats. Genet. Vaccines Ther., 6, 2008, 9.
46. Chen, B.D., He, C.H., Chen, X.C., Pan, S., Liu, F., Ma, X., Li, X.M., Gai, M.T., Tao, J., Ma, Y.T., et al. Targeting transgene to the heart and liver with AAV9 by different promoters. Clin. Exp. Pharmacol. Physiol. 42 (2015), 1108–1117.
47. Dashkoff, J., Lerner, E.P., Truong, N., Klickstein, J.A., Fan, Z., Mu, D., Maguire, C.A., Hyman, B.T., Hudry, E., Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9. Mol. Ther. Methods Clin. Dev., 3, 2016, 16081.
48. Zincarelli, C., Soltys, S., Rengo, G., Rabinowitz, J.E., Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16 (2008), 1073–1080.
49. Aslanidi, G., Lamb, K., Zolotukhin, S., An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc. Natl. Acad. Sci. USA 106 (2009), 5059–5064.
50. Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T.J. Jr., Chiodo, V.A., Phillipsberg, T., Muzyczka, N., Hauswirth, W.W., et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002), 158–167.
51. Xiao, X., Li, J., Samulski, R.J., Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72 (1998), 2224–2232.